Precision Biosensor

Precision Biosensor Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is 220.87. In the previous year, Cash Conversion Cycle (CCC) was 366.65 — a change of -39.76% (lower).

Cash Conversion Cycle

220.87

YoY

-39.76%

Last updated:

Cash Conversion Cycle (CCC) of Precision Biosensor is 2025 220.87 . Cash Conversion Cycle (CCC) of Precision Biosensor was 2024 366.65 . It decreases by -39.76% lower compared to the previous year.

The Precision Biosensor Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
383.73 KRW
Jan 1, 2019
307.84 KRW
Jan 1, 2020
471.00 KRW
Jan 1, 2021
268.32 KRW
Jan 1, 2022
265.86 KRW
Jan 1, 2023
371.67 KRW
Jan 1, 2024
366.65 KRW
Jan 1, 2025
220.87 KRW
The Precision Biosensor Cash Conversion Cycle history
YEARCash Conversion CycleYoY
220.87-39.76%
366.65-1.35%
371.67+39.80%
265.86-0.91%
268.32-43.03%
471.00+53.00%
307.84-19.78%
383.73-4.23%
400.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Cash Conversion Cycle (CCC) of Precision Biosensor is 220.87 in 2025.

Cash Conversion Cycle (CCC) of Precision Biosensor changed from 366.65 to 220.87, representing a -39.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Precision Biosensor with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Precision Biosensor

All Key Metrics — Precision Biosensor